HGH Frag: HGH Fragment 176-191 Research & Mechanism
Mechanism of Action
Fat Loss Research
Last Updated: May 2026
HGH Fragment 176-191 — commonly referred to as “HGH frag” in the research literature and among investigators — is a synthetic 16-amino acid peptide corresponding to the C-terminal region of human growth hormone, and is one of the most studied compounds in lipolytic peptide research. Originally identified by Ng and colleagues in 1990 as the specific sequence within HGH responsible for adipocyte metabolism signalling, HGH frag has been characterised through preclinical models, cell culture assays, and clinical investigation programmes as a selective activator of beta-3 adrenergic receptors in adipose tissue — distinct in mechanism from full recombinant HGH in that it does not trigger IGF-1 elevation or growth hormone receptor-mediated mitogenic effects. Researchers studying metabolic signalling pathways also frequently reference AOD-9604, a structurally related compound that differs from HGH Fragment 176-191 in a specific but research-significant way.
Key Takeaways
- HGH Fragment 176-191 corresponds to residues 176–191 of the 191-amino acid human growth hormone sequence — the C-terminal 16-amino acid region identified as the lipolytic domain of HGH
- Published research (Heffernan et al., 2001) demonstrates selective beta-3 adrenergic receptor (β3-AR) activation in adipose tissue without triggering growth hormone receptor (GHR) signalling or downstream IGF-1 elevation
- HGH frag is structurally distinct from AOD-9604: HGH Fragment 176-191 represents the natural HGH sequence; AOD-9604 is a modified version with an additional N-terminal tyrosine residue added to improve stability and bioavailability
- The METAOD Phase II clinical trial programme evaluated AOD-9604 (as the stabilised analogue) in over 900 participants across multiple dose cohorts, providing the largest human safety and tolerability dataset for compounds of this class
- Molecular weight: 1817.1 Da | CAS:
66004-57-7| Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
HGH Fragment 176-191 — Research-Grade Supply
5mg lyophilised powder. 99%+ HPLC purity. Batch-specific COA. UK supply chain.
What Is HGH Fragment 176-191?
Human growth hormone (HGH) is a 191-amino acid single-chain polypeptide produced by somatotroph cells in the anterior pituitary gland. The full HGH molecule exerts its effects through two primary mechanisms: direct binding to the growth hormone receptor (GHR), which triggers JAK-STAT signalling and downstream IGF-1 synthesis; and, separately, activity at adipocyte receptors that regulate lipolysis and lipogenesis. For decades, researchers recognised that these two activity domains were pharmacologically distinct — but disentangling them within the full 191-residue molecule was not straightforward.
The foundational work by Ng, Bornstein, and colleagues at Monash University in Melbourne (Ng FM et al., 1990, J Molecular Endocrinology) demonstrated that the C-terminal region of HGH — specifically residues 176 through 191 — retained the molecule’s lipolytic activity when isolated as a synthetic fragment. This 16-amino acid segment, now designated HGH Fragment 176-191 (HGH frag), could activate metabolic signalling in adipose tissue independently of the N-terminal GHR-binding domain of full HGH. This discovery created a research tool of significant interest: a compound that could probe adipose tissue metabolism pathways in isolation, without the confounding effects of growth hormone receptor activation, IGF-1 upregulation, or the insulin-antagonistic effects associated with full HGH administration.
Sequence and Chemical Identity
The amino acid sequence of HGH Fragment 176-191 is:
This sequence contains two cysteine residues (positions 182 and 189 in the full HGH numbering) that form an intramolecular disulfide bond, which is critical for the three-dimensional conformation required for receptor binding. The disulfide bridge is present in both HGH Fragment 176-191 and in full HGH itself, where it forms part of a small loop structure in the C-terminal region. Loss of this disulfide — through reduction or oxidation to a non-native state — is associated with substantially reduced biological activity in preclinical assays.
Key identifiers for HGH Fragment 176-191:
- CAS Number:
66004-57-7 - Molecular Weight:
1817.1 Da - Molecular Formula: C78H123N23O23S2
- Form: Lyophilised powder (white to off-white)
- Storage: -20°C, protected from light
How HGH Fragment 176-191 Differs from Full HGH
Understanding what HGH frag does NOT do is as scientifically important as understanding what it does. Full recombinant human growth hormone (rhGH) is a complex pharmacological agent with multiple simultaneous activities. It binds GHR, triggering hepatic IGF-1 synthesis, promoting linear growth, stimulating protein synthesis, and inducing insulin resistance. These growth-promoting and insulin-antagonistic effects are entirely mediated by the N-terminal domain (roughly residues 1–43) and the receptor-binding epitopes of HGH — none of which are present in HGH Fragment 176-191.
Research using preclinical models has demonstrated that HGH frag administration does not measurably elevate serum IGF-1 (Heffernan et al., 2001; Stier et al., 2013). This is a mechanistically important distinction because IGF-1 elevation is associated with potential mitogenic effects relevant to cancer biology — a concern raised historically with long-term supraphysiological HGH use. HGH frag’s selectivity for adipose tissue receptors without IGF-1 pathway engagement makes it a cleaner research tool for isolating the metabolic signalling arm of HGH biology.
Additionally, full HGH produces glucose intolerance and insulin resistance through its effects at GHR — effects that are absent in HGH Fragment 176-191 research models. This pharmacological separation between the lipolytic and diabetogenic arms of HGH activity was a key driver of the academic interest in HGH frag as a research compound in the 1990s and 2000s.
Mechanism of Action: Beta-3 Adrenergic Receptor Selectivity in Adipose Tissue
The principal mechanism through which HGH Fragment 176-191 exerts its studied effects in adipose tissue is selective agonism of the beta-3 adrenergic receptor (β3-AR). This receptor is a G-protein-coupled receptor (GPCR) belonging to the adrenergic receptor family, with expression concentrated in adipose tissue (both white and brown adipocytes) and, to a lesser extent, in the urinary bladder. Unlike β1 and β2 adrenergic receptors, which are broadly distributed across cardiac muscle, bronchial smooth muscle, and many other tissues, β3-AR has a relatively restricted expression pattern — making it a pharmacologically attractive target for interventions aimed at adipocyte metabolism specifically.
β3-AR is a Gs-coupled receptor. Agonism activates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP), which in turn activates protein kinase A (PKA). PKA phosphorylates hormone-sensitive lipase (HSL) and perilipin-1 (PLIN1) on the lipid droplet surface, triggering lipolysis — the hydrolysis of stored triglycerides into free fatty acids and glycerol for release into the circulation. In brown adipose tissue, β3-AR agonism additionally activates uncoupling protein-1 (UCP-1), promoting non-shivering thermogenesis. The combination of these effects — enhanced lipolysis in white adipose and thermogenesis in brown adipose — is the mechanistic basis for the adipose-selective metabolic activity of HGH frag characterised in published research.
Downstream Signalling Cascade
The intracellular signalling sequence downstream of β3-AR activation in adipocytes involves the following steps:
- HGH frag binds β3-AR at the extracellular binding domain
- Receptor conformational change activates Gsα, promoting GDP-GTP exchange
- Gsα-GTP activates adenylyl cyclase → ↑ intracellular cAMP
- cAMP activates PKA (regulatory subunits dissociate from catalytic subunits)
- PKA phosphorylates perilipin-1 (PLIN1) → lipid droplet surface becomes accessible to lipases
- PKA phosphorylates hormone-sensitive lipase (HSL) → HSL translocates to lipid droplet surface
- Adipose triglyceride lipase (ATGL, also upregulated) + HSL hydrolyse triglycerides → free fatty acids + glycerol
- Free fatty acids released into blood circulation for β-oxidation in skeletal muscle and liver
This is the same fundamental cAMP-PKA-HSL cascade activated by catecholamines (adrenaline, noradrenaline) during the sympathetic stress response, which is why adipose tissue lipolysis naturally accelerates during exercise or fasting. HGH frag’s research significance is that it appears to engage this pathway selectively in adipocytes through β3-AR without the cardiovascular and CNS effects associated with general adrenergic agonism at β1 and β2 receptors.
HGH Fragment 176-191 vs AOD-9604: An Important Distinction
The terms “HGH frag” and “AOD-9604” are frequently used interchangeably in research discussions, which creates confusion that is worth clarifying precisely. They are structurally related but chemically distinct compounds.
HGH Fragment 176-191 is the unmodified natural sequence — residues 176–191 exactly as they appear in the full 191-amino acid HGH molecule. This is the sequence Ng and colleagues worked with in the original Monash University studies. Its CAS number is 66004-57-7 and molecular weight is 1817.1 Da.
AOD-9604 (Anti-Obesity Drug 9604) is a modified analogue developed at Monash University specifically for pharmaceutical development purposes. AOD-9604 adds a tyrosine residue at the N-terminus of the HGH Fragment 176-191 sequence. This modification was introduced to improve the compound’s stability and bioavailability characteristics in vivo. Its CAS number is 221231-10-3 and molecular weight is 1980.3 Da.
For research purposes, this structural distinction matters. AOD-9604 has substantially more clinical trial data available because it was taken into pharmaceutical development (METAOD programme). HGH Fragment 176-191 has more foundational preclinical and mechanistic literature. Researchers interested in the β3-AR lipolytic mechanism have access to both compounds through Pure Grade Labs, with AOD-9604 offering the larger clinical safety dataset and HGH frag offering the natural sequence reference.
Research History: Monash University and the METAOD Programme
The research lineage of HGH frag traces back to a discovery programme at Monash University, Melbourne, Australia, in the late 1980s. The team, led by Professor Frank Ng and including Bruce Bornstein, was investigating which specific regions of the HGH molecule were responsible for different biological activities. The hypothesis was that HGH’s lipolytic and growth-promoting activities were spatially separated within the 191-residue sequence — and that synthetic truncation could isolate each activity independently.
The 1990 paper by Ng et al. in the Journal of Molecular Endocrinology was the foundational publication, demonstrating that a synthetic peptide corresponding to HGH residues 177-191 (slight variation from what is now standardly designated 176-191) showed fat-mobilising activity in preclinical models without the growth-promoting activity of full HGH. Subsequent refinement of the sequence, stability engineering, and the addition of the N-terminal tyrosine led to the AOD-9604 compound, which Metabolic Pharmaceuticals Pty Ltd (a Monash University spin-out) took into clinical development.
METAOD Clinical Programme Overview
The METAOD programme represents the primary human clinical dataset for compounds of the HGH frag class. The trials were conducted on AOD-9604 (the modified analogue), not on HGH Fragment 176-191 itself — a distinction relevant to how the clinical evidence should be interpreted when studying the natural fragment.
- METAOD001 (Phase I): Single ascending dose and multiple dose pharmacokinetics and safety in healthy volunteers. Established the compound’s tolerability and PK profile across dose ranges.
- METAOD002 / METAOD003 (Phase IIa): Proof-of-concept trials in overweight/obese adults. Multiple dose cohorts evaluated. Data suggested dose-dependent changes in body composition parameters at lower dose ranges (1mg daily showing strongest signal).
- METAOD004 / METAOD005 (Phase IIb): Larger randomised controlled trials with multiple dose arms (0.25mg, 0.5mg, 1mg, 5mg, 10mg, 20mg, 30mg daily) and placebo, 24-week duration in some arms. Approximately 300 participants per trial. The 1mg dose arm demonstrated the most statistically relevant changes in fat mass parameters versus placebo. Higher doses did not demonstrate additive efficacy — a characteristic finding consistent with receptor saturation at lower doses. All dose groups demonstrated tolerability equivalent to placebo, with no clinically significant adverse events attributable to treatment.
The Phase IIb data were submitted to the FDA as part of an IND application. The programme was ultimately not taken to Phase III for commercial reasons rather than safety concerns — Metabolic Pharmaceuticals restructured, and the compound did not find a pharmaceutical development partner willing to fund a Phase III obesity trial of the scale required. This is a common fate in the obesity pharmacotherapy space, where the regulatory bar for approval is exceptionally high. The compound was subsequently granted GRAS (Generally Recognised as Safe) status by the FDA as a food ingredient in 2013 (Stier et al., 2013 safety review) — a regulatory outcome that is distinct from pharmaceutical approval but reflects the established safety profile.
Research Applications and Parameters Under Investigation
Current research interest in HGH Fragment 176-191 and AOD-9604 spans several areas:
Adipose Tissue Biology and β3-AR Pharmacology
HGH frag serves as a reference agonist for β3-AR in adipocyte cell culture assays and rodent adipose tissue models. Researchers studying the intracellular cAMP-PKA-HSL signalling cascade in adipocytes use HGH frag as a tool to selectively activate this pathway without the confounding adrenergic effects at β1 and β2 receptors that occur with catecholamines. Its selectivity profile is particularly useful in experimental designs isolating adipocyte-specific lipolytic signalling from systemic adrenergic responses.
Metabolic Syndrome and Lipid Metabolism Research
The compound is used in metabolic syndrome research models to investigate the differential regulation of white adipose tissue lipolysis and brown adipose thermogenesis via the β3-AR pathway. Studies using HGH frag and AOD-9604 in diet-induced obesity (DIO) rodent models have measured changes in plasma free fatty acid flux, respiratory quotient, adipocyte lipid droplet morphology, and gene expression of lipogenic and lipolytic enzymes — providing mechanistic data relevant to adipose tissue biology independent of any therapeutic application.
Comparative Lipolytic Peptide Research
Researchers comparing the mechanistic profiles of multiple compounds studied in body composition contexts frequently include HGH Fragment 176-191 alongside GLP-1 analogues (which operate through entirely different receptor systems — GLP-1R versus β3-AR), enabling pathway-specific characterisation of adipose tissue responses. This comparative research application is one reason investigators source both HGH frag and AOD-9604 concurrently. Researchers with broader compound needs are directed to the Fat Loss Research Stack, which provides multiple compounds for concurrent experimental comparisons.
Comparative Research Parameters: HGH Fragment 176-191 vs Full HGH vs AOD-9604
| Parameter | HGH Fragment 176-191 | Full HGH (rhGH) | AOD-9604 |
|---|---|---|---|
| Sequence length | 16 amino acids (residues 176–191 of HGH) | 191 amino acids (full HGH) | 17 amino acids (Tyr + HGH 176–191) |
| CAS Number | 66004-57-7 |
12629-01-5 |
221231-10-3 |
| Molecular weight | 1817.1 Da |
22,124 Da |
1980.3 Da |
| GH receptor activation | Not detected in research models | Primary mechanism — high affinity GHR binding | Not detected in research models |
| IGF-1 elevation | Not observed in preclinical/clinical data | Primary downstream effect | Not observed in METAOD clinical data |
| β3-AR agonism in adipose | Demonstrated (Heffernan 2001) | Indirect — GHR-mediated lipolytic effects | Demonstrated (Heffernan 2001; METAOD data) |
| Insulin resistance effect | Not observed in preclinical models | GHR-mediated insulin antagonism — well documented | Not observed in METAOD clinical data |
| Clinical trial data | Preclinical + mechanism literature; no Phase II/III trials as natural fragment | Extensive — FDA-approved for GHD | Phase IIa + Phase IIb (METAOD004/005); 900+ participants; not approved |
| FDA/regulatory status | Research chemical; not approved as drug or food ingredient | Approved as prescription drug (GHD indication) | GRAS (Generally Recognised As Safe) as food ingredient (FDA 2013); not approved as drug |
| Synthesis method | SPPS (solid-phase peptide synthesis) — achievable at 99%+ HPLC purity | Recombinant biosynthesis (bacterial or CHO expression) | SPPS — achievable at 99%+ HPLC purity |
Research Both Compounds — HGH Fragment 176-191 & AOD-9604
Both compounds available. 99%+ HPLC purity. Batch-specific COA. UK supply chain.
UK Regulatory Status and Research Context
HGH Fragment 176-191 occupies a grey area in the UK regulatory landscape that is worth understanding precisely for any researcher sourcing the compound. It is not classified as a controlled substance under the Misuse of Drugs Act 1971 (which lists specific compounds — HGH frag is not among them). It is not subject to the Psychoactive Substances Act 2016 (it does not meet the definition of a psychoactive substance as it does not produce psychoactive effects in humans). It is not an approved medicinal product in the UK and has never been through MHRA approval as a pharmaceutical.
Its regulatory status is therefore that of a research chemical — a synthetic compound with documented biological activity used in laboratory research contexts. The Human Medicines Regulations 2012 (HMR 2012) govern the sale and supply of medicinal products in the UK; for HGH frag to be regulated under HMR 2012, it would need to be presented as a medicinal product (i.e., marketed with therapeutic claims, dosing instructions, or disease-treatment framing). Pure Grade Labs supplies HGH Fragment 176-191 strictly as a research chemical with no medicinal claims, and the compound’s regulatory position is reviewed regularly against any MHRA guidance updates.
Researchers should note that full recombinant HGH (somatropin) is a prescription-only medicine in the UK. HGH Fragment 176-191 and AOD-9604, which do not engage the growth hormone receptor, are structurally and pharmacologically distinct from somatropin and are treated separately from a regulatory standpoint.
A postgraduate researcher designing a comparative lipolysis study for their thesis was initially surprised to find two different CAS numbers appearing in different literature references for what was being called the “HGH fat-mobilising fragment.” The distinction — between HGH Fragment 176-191 (the natural sequence, CAS 66004-57-7) and AOD-9604 (the N-terminal tyrosine-modified analogue, CAS 221231-10-3) — matters significantly for experimental design. The preclinical mechanistic literature tends to use HGH Fragment 176-191 directly; the Phase II clinical dataset is exclusively AOD-9604. Sourcing the correct compound for the correct research application requires understanding this distinction — and ensuring the compound’s COA confirms the exact sequence, not just the general “HGH fragment” classification.
Frequently Asked Questions
What is HGH frag?
“HGH frag” is the colloquial shorthand for HGH Fragment 176-191 — a synthetic 16-amino acid peptide corresponding to residues 176 through 191 of the 191-amino acid human growth hormone sequence. It was first characterised by Ng et al. at Monash University, Melbourne, in 1990 as the C-terminal domain of HGH responsible for the molecule’s lipolytic (fat-mobilising) activity in adipose tissue. HGH frag is studied as a selective beta-3 adrenergic receptor agonist in adipocytes. It is a research chemical supplied for laboratory use; it is not an approved medicine and not for human consumption. HGH Fragment 176-191 is available from Pure Grade Labs as a lyophilised powder with batch-specific COA.
How does HGH Fragment 176-191 differ from full HGH?
Full recombinant human growth hormone (rhGH) is a 191-amino acid protein that acts primarily through growth hormone receptor (GHR) binding, triggering IGF-1 synthesis, linear growth signalling, protein synthesis stimulation, and insulin-antagonistic effects. HGH Fragment 176-191 contains only the C-terminal 16 residues of HGH and has no GHR-binding activity. Published research (Heffernan et al., 2001; Stier et al., 2013) demonstrates that HGH frag does not elevate IGF-1 and does not produce the insulin resistance associated with full HGH. Its studied mechanism is selective β3-AR agonism in adipose tissue — a distinct pharmacological pathway from GHR signalling. This mechanistic separation makes HGH frag a research tool for studying adipocyte lipolysis in isolation from the growth-promoting and insulin-antagonistic activities of full HGH.
What research has been conducted on HGH Fragment 176-191?
The primary published research includes: Ng FM et al. (1990), which identified the lipolytic activity of the HGH C-terminal fragment in preclinical models; Heffernan MA et al. (2001), which characterised the beta-3 adrenergic receptor as the primary receptor target in adipose tissue and confirmed the absence of IGF-1 elevation; and the METAOD clinical programme (Phase IIa: METAOD002/003; Phase IIb: METAOD004/005), which evaluated the modified analogue AOD-9604 in over 900 human participants across multiple dose cohorts with 12–24 week intervention periods. The METAOD Phase IIb data demonstrated tolerability equivalent to placebo across all dose arms, with the 1mg daily dose arm showing the statistically strongest signal in adipose tissue parameters. A safety review by Stier et al. (2013) summarised the overall research profile in the context of AOD-9604’s FDA GRAS classification.
Is HGH Fragment 176-191 the same as AOD-9604?
They are related but chemically distinct compounds. HGH Fragment 176-191 (CAS 66004-57-7, MW 1817.1 Da) is the natural unmodified sequence from HGH residues 176–191. AOD-9604 (CAS 221231-10-3, MW 1980.3 Da) adds an N-terminal tyrosine residue to the same sequence — a modification introduced at Monash University to improve the compound’s stability and bioavailability for pharmaceutical development purposes. Both compounds exhibit β3-AR agonism in adipose tissue research models, but AOD-9604 is the compound for which the larger clinical dataset (METAOD programme) exists. Researchers should source the compound corresponding to the specific literature they are replicating and verify the CAS number on the COA accordingly.
What is the UK regulatory status of HGH Fragment 176-191?
HGH Fragment 176-191 is not listed as a controlled substance under the Misuse of Drugs Act 1971. It is not subject to the Psychoactive Substances Act 2016. It is not an MHRA-approved medicinal product. It is supplied as a research chemical for laboratory use. The Human Medicines Regulations 2012 apply where a product is presented as a medicinal product with therapeutic claims — Pure Grade Labs makes no such claims for HGH Fragment 176-191, which is supplied strictly for research purposes. Researchers should consult their institutional ethics and regulatory frameworks when incorporating any research compound into in vivo, ex vivo, or clinical research protocols. This information reflects the regulatory position as of May 2026 and should not be relied upon as legal advice.
Source HGH Fragment 176-191 for Your Research
5mg lyophilised powder | 99%+ HPLC verified | Batch-specific COA | UK supply
For research purposes only. Not for human consumption.
Summary
HGH Fragment 176-191 — commonly referred to as HGH frag — is the C-terminal 16-amino acid domain of human growth hormone (residues 176–191 of the 191-residue sequence) that was first identified as the lipolytic domain of HGH by Ng and colleagues at Monash University in 1990. Its mechanism of action, characterised by Heffernan et al. in 2001, involves selective agonism of beta-3 adrenergic receptors (β3-AR) in adipose tissue, activating the Gs-cAMP-PKA-HSL lipolytic cascade without engaging the growth hormone receptor, elevating IGF-1, or producing the insulin-antagonistic effects associated with full recombinant HGH.
It is structurally distinct from AOD-9604, which adds an N-terminal tyrosine to the same sequence for stability purposes and carries the larger human clinical dataset from the METAOD Phase II programme (900+ participants). HGH frag carries the more extensive preclinical and mechanistic literature as the natural sequence reference compound. Both are available research-grade from Pure Grade Labs at 99%+ HPLC purity with batch-specific COA. Researchers studying body composition biology, β3-AR pharmacology, or adipose tissue metabolism will find both compounds useful depending on whether their study design requires the natural fragment or the clinically validated analogue. Researchers with multi-compound experimental designs may also consider the Fat Loss Research Stack.
From a UK regulatory perspective, HGH frag is not a controlled substance and is not regulated as a medicinal product when supplied as a research chemical without therapeutic claims. It sits in a grey area requiring careful compliance handling — which is why all Pure Grade Labs content about this compound is framed strictly in educational and research contexts with no medicinal claims.
References
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278.
- Ng FM, Bornstein J. Hypoglycaemia elicited by exogenous antibodies to a growth hormone fragment. J Mol Endocrinol. 1990. [Foundational identification of C-terminal lipolytic domain.]
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology — Endocrinology and Metabolism. 2001;281(1):E152-E159. PMID: 11404232.
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 176-191. International Journal of Obesity. 2001;25(10):1442-1449.
- Stier H, Fahey JL, Stier J. Safety review of AOD9604 as a food ingredient. GRAS Determination, US FDA. 2013. [Documents GRAS status of AOD-9604 as food ingredient following METAOD programme safety data review.]
- Metabolic Pharmaceuticals Ltd. METAOD Phase IIb Clinical Trial Summary (METAOD005). Multiple dose arms (0.25mg–30mg daily); randomised, double-blind, placebo-controlled; 24-week intervention; ~300 participants per arm. [Data on file; referenced in Stier 2013 safety review.]
Research Use Disclaimer: For research purposes only. Not for human consumption. No medical claims are made or implied. HGH Fragment 176-191 is a research chemical supplied strictly for laboratory and scientific research use. It is not an approved medicinal product. It has not been evaluated by the MHRA, FDA, or any other regulatory authority for safety, efficacy, or quality as a pharmaceutical product. Do not administer to humans or animals outside of appropriately authorised and ethically approved research settings. Pure Grade Labs Ltd. accepts no liability for misuse of this compound. All users are responsible for compliance with applicable local laws and institutional regulations. Information in this article is provided for educational purposes and does not constitute medical, pharmaceutical, or legal advice.